Our 4 global businesses include generics, biosimilars, research services and novel biologics. They represent Biocon’s risk-balanced strategy, underpinned by agile network connections, a robust pipeline and a timely ‘emerging markets’ orientation.

Biocon is addressing global medical needs through a portfolio of differentiated and high quality, life-saving biotherapeutics. We have used innovative science to bring competition for some of the world’s most expensive medicines through our generics and biosimilars, thus enabling affordable access to advanced therapies for millions of ...

Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other ...

Report adverse event/ side effects and/or product complaints for Biocon products. Click here to report adverse event/side effects/product complaints and/or submit medical queries for Biocon Biologics Limited & BBL Affiliate products.

Biocon is an innovation led fully integrated biopharmaceutical company that has developed affordable biosimilars, novel biologics and complex APIs. Leader in fermentation based biopharmaceuticals. Global scale manufacturing set up for biologics, biosimilars. High end scientific talent, research and development infrastructure.

It’s a chance at Biocon to work alongside some of the brightest minds in research, healthcare, pharmaceutical, biotechnology & business sector

We are a global biopharmaceutical company driven by the belief that everyone, everywhere deserves access to affordable, quality medicines. At Biocon, we pioneer novel approaches to improve patient outcomes today, for a better tomorrow.

Biocon is a unique global biopharmaceutical company changing patients’ lives in over 120 countries. From drug discovery to drug delivery, we make life-saving medicines for the most feared diseases, to extend and significantly improve the quality of life.

Our 4 global businesses include generics, biosimilars, research services and novel biologics. They represent Biocon’s risk-balanced strategy, underpinned by agile network connections, a robust pipeline and a timely ‘emerging markets’ orientation.

2022年11月29日 · Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), announced today that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of its partner Viatris Inc. (NASDAQ: VTRS).